Leerink Partners Maintains Outperform on Belite Bio, Raises Price Target to $215
Belite Bio (BLTE) Q3 2026 Earnings Call Transcript
What Belite Bio (BLTE) Said on Its Q3 Earnings Call
Belite Bio, Inc (BLTE) Q3 2026 Earnings Call Transcript
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
Belite Bio Q3 EPS $(0.65) Beats $(0.80) Estimate
Belite Bio (BLTE) Stock May Trade Above Fair Value On Book Value
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
Belite Bio Wins Nasdaq Global Select Listing, Trading Starts Oct. 19
Belite Bio Stock In Focus After Stargardt Drug Filings In Three Markets
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio Files Marketing Authorization Application In Singapore, U.K., Switzerland For Tinlarebant To Treat Stargardt Disease Type 1
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross
Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234
Belite Bio On Track For A Potential Blockbuster Launch In 2027
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.